eMedicine Specialties > Infectious Diseases > Lower Respiratory Tract Infections

Pneumococcal Infections

Author: Dawn F Muench, MD, Assistant Professor of Pediatrics, Uniformed Services University of the Health Sciences; Fellow in Pediatric Infectious Disease, Department of Pediatrics, National Capital Consortium, Walter Reed Army Medical Center
Coauthor(s): Michael Rajnik, MD, Assistant Professor, Department of Pediatrics, Acting Program Director, Pediatric Infectious Disease Fellowship Program, Uniformed Services University of the Health Sciences
Contributor Information and Disclosures

Updated: May 16, 2008

Introduction

Background

Streptococcus pneumoniae is a gram-positive, catalase-negative cocci that has remained an extremely important human bacterial pathogen since its initial recognition in the late 1800s. The term pneumococcus gained widespread use by the late 1880s, when it was recognized as the most common cause of bacterial lobar pneumonia.

Worldwide, it remains the most common cause of community-acquired pneumonia (CAP), bacterial meningitisbacteremia, and otitis media. S pneumoniae infection is also an important cause of sinusitis, septic arthritis, osteomyelitis, peritonitis, and endocarditis and an infrequent cause of other less common diseases.

Pathophysiology

Adherence and invasion
 
S pneumoniae is an example of a typical extracellular bacterial pathogen. Pathogenicity requires adherence to host cells, along with the ability to replicate and to escape clearance and/or phagocytosis. The organism must then gain access to areas where it can manifest infection, either via direct extension or lymphatic or hematogenous spread.

The rates of pneumococcal colonization in healthy children and adults provide information about the success of adherence and replication of the pneumococcus. After colonization, organisms may gain access to areas of the upper and/or lower respiratory tracts (sinuses, bronchi, eustachian tubes) by direct extension. Under normal conditions in a healthy host, anatomic and ciliary clearance mechanisms prevent clinical infection. However, clearance may be inhibited by chronic (smoking, allergies, bronchitis) or acute (viral infection, allergies) factors, which can lead to infection. Alternatively, pneumococci may reach normally sterile areas, such as the blood, peritoneum, cerebrospinal fluid, or joint fluid, by hematogenous spread after mucosal invasion. In the absence of previously acquired serotype-specific antibodies (see below), clinically apparent infection is likely to occur.

Capsule
 
Other than some isolates associated with conjunctivitis outbreaks, essentially all clinical isolates of S pneumoniae are encapsulated. Repeating oligosaccharides that make up the capsule of an individual bacterial isolate are transported to the cell surface, where they bind tightly with the cell-wall polysaccharides. Based on antigenic differences within these capsular polysaccharides, 90 serotypes of S pneumoniae have been identified. 
 
The virulence of each organism is determined in part by the makeup and amount of capsule present. In a pneumococcus-naive host (or in the absence of antibody to pneumococcal capsule) host-cell phagocytosis is severely limited because of the inhibition of phagocytosis and the inhibition of the activation of the classic complement pathway. In addition, in vitro and in vivo studies of clinical isolates have shown that pneumococci have the ability to obtain DNA from other pneumococci (or other bacteria) via transformation, allowing them to switch to serotypically distinct capsular types. 

There are 2 recognized numbering systems based on pneumococcal serotypes. In the American system, the serotypes were numbered in order of discovery, with lower numbers corresponding to serotypes that more frequently cause clinical disease, meaning that they were identified earlier. The Danish numbering system is based on grouping of serotypes with similar antigenicity and is more widely accepted and used worldwide. Today, serotyping provides important epidemiological information, especially with the increasingly widespread use of vaccination, but rarely provides timely clinical information.

The Quellung reaction is demonstrated by combining sera of previously immunized animals with capsular antigen. Agglutination causes capsule refractility and the ability to observe the capsule microscopically.

Toxins and other virulence factors

 
Pneumococcal isolates produce few toxins; however, all serotypes produce pneumolysin, which is an important virulence factor that acts as a cytotoxin and activates the complement system. In addition, pneumolysin causes a release of tumor necrosis factor-alpha and interleukin-1.

Other potential virulence factors include cell surface proteins such as surface protein A and surface adhesin A and enzymes such as autolysin, neuraminidase, and hyaluronidase. The contributions of these substances to pneumococcal virulence are being studied extensively, and some are being investigated as potential vaccine constituents.

Complement activation 
 
Much of the clinical severity of pneumococcal disease is due to the activation of the complement pathways and cytokine release, which induce a significant inflammatory response. S pneumoniae cell wall components, along with the pneumococcal capsule, activate the alternative complement pathway; antibodies to the cell wall polysaccharides activate the classic complement pathway. Cell wall proteins, autolysin, and DNA released from bacterial breakdown all contribute to the production of cytokines, inducing further inflammation.

Frequency

United States

Colonization

S pneumoniae remains an important pathogen in large part because of its ability to first colonize the nasopharynx efficiently. Studies performed in the United States prior to universal vaccination recommendations have shown average carriage rates of 40-50% in healthy children and 20-30% in healthy adults. Factors such as age, daycare attendance, composition of household, immune status, antibiotic use, and others obviously affect these numbers.1,2,3 With the implementation of childhood vaccination with the heptavalent conjugate vaccine for S pneumoniae, the colonization rates have decreased in children receiving the vaccine and in adults and other children in their household because of the phenomenon of herd immunity.

S pneumoniae infection is the most common cause of CAP, bacterial meningitis, bacteremia, and otitis media in the United States. There is a clear seasonality, with infections peaking in the fall and winter months.

Noninvasive disease

In adults admitted to the hospital for pneumonia treatment, S pneumoniae remains the most common organism isolated. Annual rates of pneumonia proven to be caused by S pneumoniae infection in the United States are estimated to be around 175,000; however, this number is likely a gross underestimate, as a definite cause is not determined in most cases of pneumonia treated each year. S pneumoniae infection is an important cause of bacterial co-infection in patients with influenza and can increase the morbidity and mortality in these patients. The most common cause of death due to pneumococcal disease throughout the world is pneumonia.

S pneumoniae infection is estimated to cause over 7 million cases of otitis media annually in the United States. These numbers have likely decreased somewhat with the advent of universal vaccinations; however, S pneumoniae infection remains the most common cause of otitis media.4,3

Invasive disease

Invasive pneumococcal disease is estimated to cause more than 50,000 cases of bacteremia and 3,000-5,000 cases of meningitis annually. Death due to invasive disease is estimated to be 6,000 persons annually, with more than half of these in adults with specific risk factors (age, immunosuppression) for severe disease. Such risk factors are an indication for vaccination.4,3

International

Despite the worldwide importance of disease due to S pneumoniae infection, very little information is available on the extent of pneumococcal disease, particularly in developing countries.

Children

In developing countries, pneumococcus remains the most common and important disease-causing organism in infants. Although exact numbers are difficult to obtain, it is estimated that pneumococcus infection is responsible for more than one million of the 2.6 million annual deaths due to acute respiratory infection in children younger than 5 years.

Estimates of pneumococcal disease in Gambian children show high rates of infection in the first year of life (≥500 per 100,000 children).5 Latin American studies also show a particularly high risk in infants younger than 6 months, and children in southern India have higher rates of colonization at younger ages compared with US children, according to US clinical studies. Some particular populations, such as indigenous Australians and minority Israeli persons, also have disproportionately higher rates of disease, similar to the native Alaskan and native Indian populations in the United States, although determining the role of socioeconomic factors in the higher incidence of disease in these populations is difficult.5

In Europe, children younger than 2 years constitute the population most at risk for pneumococcal infection, with rates decreasing as persons age. The overall incidence of invasive disease is estimated to be somewhat lower in Europe (35.8 per 100,000 persons in England vs 45.3 per 100,000 persons in Finland vs 235 per 100,000 persons in the United States), although many have postulated that this may be due in part to the more liberal blood-culture collection practices in the American health care system.5

Adults

Even fewer data are available on the worldwide incidence of pneumococcal disease in adults. As in the United States, the most common cause of CAP in Europe is S pneumoniae infection, affecting approximately 100 per 100,000 adults each year. Overall rates of febrile bacteremia and meningitis are also similar, (15–19 per 100,000 adults and 1–2 per 100,000 adults, respectively), with the risk for these diseases increased in elderly and infant populations.6

Because no population-based data on pneumococcal disease in adults in developing countries are available, estimates of disease burden are based on small clinical studies, vaccine trials, extrapolation from data in developed countries, and studies of persons at high risk for disease. The information gleaned from these sources suggests that the incidence of and mortality from pneumococcal disease are high; however, further studies are greatly needed.7

Mortality/Morbidity

Although exact rates are difficult to determine, the World Health Organization (WHO) estimates that, worldwide, 1.6 million deaths were caused by pneumococcal disease in 2005, with 700,000 to 1 million of these occurring in children younger than 5 years.8 Even in patients in developed countries, invasive pneumococcal disease carries a high mortality rate—an average of 10–20% in adults with pneumococcal pneumonia, with much higher rates in those with risk factors for disease.9

Race

In the United States, invasive pneumococcal disease is more common in native Alaskans, Navajo and Apache Indians, and African Americans than in other ethnic groups. Some studies have shown this difference persists even when the results are controlled for socioeconomic factors, and the reasons for this discrepancy among certain populations are unclear.2

Sex

Most clinical studies of pneumococcal disease show a slight male predilection for disease; the reason for this is unclear.

Age

Children younger than 2 years carry the highest burden of S pneumoniae disease worldwide. In developed countries, the incidence is highest in those aged 6 months to 1 year, while, in developing countries, the disease is particularly common in children younger than 6 months.

Adults older than 55-65 years are the next most commonly affected age group worldwide.

Immunosuppressed persons of any age are at a higher risk for pneumococcal disease.

Clinical

History

After successful colonization, S pneumoniae can cause a wide range of clinical disease. By direct extension from the nasopharynx, S pneumoniae infection can manifest as otitis media, sinusitis, tracheobronchitis, bronchitis, and pneumonia. By hematogenous spread, S pneumoniae infection can cause primary bacteremia, meningitis, osteomyelitis, pericarditis, endocarditis, myositis, septic arthritis, and peritonitis.

Factors that should prompt consideration of pneumococcal disease in patients with the above conditions include the following:

  • High-risk age groups
    • Children younger than 5 years, particularly aged 2 years or younger are at an increased risk of disease. In addition, absence of breastfeeding, exposure to cigarette smoke, daycare attendance, and lack of immunization with the pneumococcal conjugate vaccine further increase the risk of disease.
    • Adults older than 55-65 years are also at an increased risk of disease.
  • Immunodeficiencies: Conditions that cause immunodeficiency, including HIV infection, malignancy, diabetes mellitus, absence of the spleen, humoral immunity defects, complement deficiencies, and neutrophil dysfunction, are associated with an increased risk of disease.
  • Conditions associated with decreased pulmonary clearance functions: These include asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), viral infections, and active/passive cigarette smoke exposure.
  • Presentation in the late fall to early spring: Pneumococcal infections peak in late fall to early spring in the Northern Hemisphere.

Physical

Clinical signs and symptoms and physical examination findings alone often fail to distinguish S pneumoniae disease from those caused by other pathogens.

Diseases Due To Direct Extension

Conjunctivitis
  • Bacterial conjunctivitis is commonly more bilateral and purulent than viral conjunctivitis.
  • S pneumoniae is found in up to one third of patients with bacterial conjunctivitis; the rate of isolates that are not susceptible to penicillin is increasing.

Otitis media

  • S pneumoniae is the most commonly isolated bacterial pathogen from children and adults with otitis media.
  • Several early studies suggested or showed that S pneumoniae otitis media is usually accompanied by fever and pain and that the fever is higher than in otitis media caused by other common bacterial pathogens.2
  • Pneumococcal disease is less likely to resolve spontaneously.
  • Eustachian tube congestion caused by a preceding viral infection is common. 
  • Increasing antibiotic resistance has led to decreased effectiveness of the antibiotics that were once used most commonly to treat otitis media.
  • S pneumoniae infection is the most common cause of mastoiditis, a complication of otitis media that was more common in the pre-antibiotic era; this complication is now more commonly associated with untreated or improperly treated cases of otitis media.

Sinusitis

  • As in otitis media, S pneumoniae is the most commonly isolated bacterial organism from patients with acute sinusitis.
  • Acute sinusitis manifestations may vary depending on the age of the patient and the developmental status of individual sinuses. In children younger than 5 years, infection is usually limited to the ethmoid and maxillary sinuses.
  • Acute sinusitis is usually preceded by a viral infection, leading to sinus mucosal swelling and ostia obstruction. This is followed by the development of a purulent discharge and cough.
  • Malodorous breath and worsening cough due to postnasal drip are often noted at night.

Acute exacerbations of chronic bronchitis

  • Acute exacerbations of chronic bronchitis manifest as a change from baseline chronic symptoms. Symptoms include shortness of breath, increased production and/or purulence of sputum, increased sputum tenacity, and cough.
  • An estimated 80% of cases of acute exacerbations of chronic bronchitis are caused by infection, with about one half of those caused by aerobic bacteria, of which S pneumoniae is the most commonly isolated organism.
  • Symptoms such as sore throat, cold symptoms, and dyspnea may indicate a viral cause.10

Pneumonia

  • Classic pneumococcal pneumonia often develops in older children and adults. It is often preceded by a viral illness that is followed by an acute onset of high fever—often with rigors, productive cough, pleural pain, dyspnea, tachypnea, tachycardia, sweats, malaise, and fatigue.
  • Patients typically appear ill and may have an anxious appearance. On careful physical examination, crackles can be heard in most patients. About half of all patients exhibit dullness to percussion, and splinting due to pain may be seen. Signs of effusion may be found on examination and include dullness to percussion at the bases and diaphragmatic motion that is decreased from that expected in light of the patient's tachypnea.
  • In children (particularly school-aged and younger children), the potential manifestations of pneumonia are broad and often nonspecific. These may include nonspecific, mild respiratory symptoms, with or without a cough on initial presentation, high fever, abdominal pain, abdominal distention, anorexia, emesis (often suggesting a primary gastrointestinal disease, and meningeal signs due to meningeal irritation with upper lobe pneumonias.
  • In elderly patients with pneumococcal pneumonia, tachypnea may be the primary presenting sign, and their temperature elevations may be mild or absent.
  • The most common complication of pneumococcal pneumonia is pleural effusion. Although up to 40% of patients with pneumococcal pneumonia may have pleural effusion, only an estimated 10% of these patients have enough fluid to aspirate, with only 2% of these patients meeting criteria for true empyema. S pneumoniae infection, as well as S aureus infection, remains a common cause of pediatric empyema.2,3,11

Invasive Disease

Meningitis
  • As a cause of meningitis, S pneumoniae usually invades the meninges via the bloodstream. Recent studies have shown that this is most likely due to pneumococcal adherence to up-regulated platelet-activating factor on vascular endothelial meningeal surfaces.
  • S pneumoniae can also directly invade the meninges after basilar skull fractures or other trauma that compromises the dura and is the most common cause of recurrent bacterial meningitis in these patients.
  • In countries with routine-vaccination policies, S pneumoniae infection is the most common cause of sporadic bacterial meningitis in both children and adults.
  • Most patients with pneumococcal meningitis present non-acutely after hours to days of developing signs and symptoms. Presenting signs and symptoms may be nonspecific and include fever, irritability, emesis, lethargy, anorexia, and malaise.
  • Neurologic signs and symptoms are usually prominent and may include mental-status changes, delirium, lethargy, nuchal rigidity with positive Brudzinski and Kernig signs, cranial nerve palsies, and other focal neurological deficits.
  • A bulging fontanelle and poor feeding may be seen infants.
  • Elderly patients may present with more indolent signs, including increasing lethargy, nonresponsiveness, or coma.
  • Twenty to 25% of patients with pneumococcal meningitis experience seizures.
  • Bacteremia may or may not be found when blood cultures are obtained.
  • Prolonged or secondary fevers are not uncommon but do not usually affect outcomes.
  • Complications of pneumococcal meningitis include hearing loss (up to half of patients), seizures, learning disabilities, mental difficulties, and palsies. 
  • Pneumococcal meningitis carries a greater risk of death and significant neurological disabilities than does meningitis of other common bacterial causes (eg, Haemophilus influenzae type B [Hib] and Neisseria meningitidis).2,3,11

Bacteremia

  • Bacteremia is the most common manifestation of invasive pneumococcal disease.
  • Most cases are primary bacteremia and are found in children younger than 2 years. It is estimated that S pneumoniae infection has been the cause of 90% of occult bacteremia (bacteremia without a source) cases in these children since the widespread use of the Hib vaccine. 
  • In adult patients, pneumococcal bacteremia is much more likely to be associated with another focal infection such as pneumonia, meningitis, or sinusitis.
  • Signs, symptoms, and physical examination findings are usually nonspecific in patients with occult bacteremia due to pneumococcal infection.
  • In most patients, fever develops within 24 hours of positive culture findings, with higher temperatures more often associated with the development of occult bacteremia.
  • A peripheral WBC count greater than 15,000 cells/μL is associated with the presence of occult bacteremia.
  • Bacteremia is less likely in patients with fever and signs or symptoms of focal infection (eg, otitis media or a viral syndrome).
  • Most cases of occult bacteremia spontaneously resolve.
  • Complications develop in an estimated 10% of patients with occult bacteremia and include meningitis, osteomyelitis, pneumonia, soft tissue and joint infections, and sepsis.
  • Patients with higher WBC counts and fever, those who have not undergone prior antibiotic therapy, and children younger than 20 months are at a higher risk for persistent bacteremia or the development of focal infection.3,2  

Joint and bone infections

S pneumoniae infection is an uncommon cause of osteomyelitis and septic arthritis, causing approximately 4% and 20% of cases in children, respectively.

  • Septic arthritis
    • Pneumococcal septic arthritis usually manifests as painful, swollen, and hot joints.
    • The ankles and knees are most commonly involved, and one or more joints may be affected.
    • Blood or synovial cultures usually grow S pneumoniae.
    • Up to half of patients with pneumococcal septic arthritis have concomitant osteomyelitis.
  • Osteomyelitis
    • The femur and humerus are most often involved in cases of pneumococcal osteomyelitis in children; the vertebral bones are often involved in adult patients.
    • Up to 20% of patients with pneumococcal osteomyelitis develop long-term sequelae, similar to rates of osteomyelitis sequelae caused by other organisms.
    • One clinical study performed by the Pediatric Multicenter Pneumococcal Surveillance Study Group (PMPSSG) showed that more than 40% of patients with joint and bone pneumococcal infections had associated bacteremia.12
    • Patients with prostheses or rheumatic fever are at increased risk for joint disease.

Soft tissue infections

  • Although uncommon, S pneumoniae infection can cause of mild to serious soft tissue infections, including cellulitis, myositis, periorbital cellulitis, and abscess.
  • Most patients have WBC counts greater than 15,000 cells/μL and elevated temperatures.
  • Physical findings are related to the site of infection and usually include redness, warmth, and tenderness of the involved area. Movement may be limited by pain and/or swelling.
  • The incidence of soft tissue infections is increased in persons with HIV infection or underlying connective tissue disease; however, most affected individuals are otherwise healthy and respond well to antibiotic therapy.{Ref2}

Peritonitis

  • Primary peritonitis (peritonitis caused by the spread of organisms via blood or lymph to the peritoneal cavity) is rare, accounting for less than 20% of peritonitis cases.
  • S pneumoniae is the most commonly isolated organism in patients with primary peritonitis.
  • Primary peritonitis in children is usually associated with underlying conditions such as nephrotic syndrome and other immunocompromising diseases.
  • In adults, primary peritonitis is usually associated with cirrhosis.
  • Females with severe pelvic inflammatory disease may develop peritonitis. In such cases, organisms may gain access to the peritoneum via the fallopian tubes from the female genital tract.
  • This is the only invasive disease caused by S pneumoniae infection that is more common in females.
  • Other persons at risk for peritonitis include persons with gastrointestinal injury, ulcers, or malignancy.
  • Presenting symptoms of peritonitis include abdominal pain, anorexia, emesis, diarrhea, and fever; children with right lower quadrant abdominal pain are often initially investigated for appendicitis.

Cardiac infections

In the antibiotic era, pneumococcal cardiac infections are rare.

  • Endocarditis
    • Involvement of native aortic and mitral valves are most common; infection can lead to valve destruction, heart failure, and embolization.
    • Presenting signs and symptoms are typical of those seen in other causes of endocarditis and include fever, new or changing murmurs, muscle and/or joint pains, sweating, fatigue, anorexia, and skin findings.
  • Pericarditis
    • Prior to the widespread use of antibiotics, S pneumoniae infection was the most common cause of purulent pericarditis in children; now, infection in childhood is extremely rare, and nearly all cases of pneumococcal pericarditis occur in adults.
    • Symptoms, signs, and examination findings may include chest and/or pleuritic pain; radiating pain to the neck, abdomen, shoulder, or back; orthopnea; dry cough; extremity swelling; anxiety; fatigue; fever; pericardial rub; and muffled heart sounds.

Causes

S pneumoniae is an encapsulated, gram-positive, catalase-negative cocci that grows as a facultative anaerobe. These organisms often appear on Gram stain as lancet-shaped diplococci that grow in chains. On blood and chocolate agar plates, a green zone (alpha-hemolysis; due to the breakdown of hemoglobin by pneumolysin) surrounds the colonies. Other identifying properties include sensitivity to optochin (which distinguishes it from other alpha-hemolytic streptococci) and bile solubility.

Predisposing conditions to pneumococcal infection are broad and often overlapping, including the following:

  • Exposure
    • Cigarette smoke
    • Alcohol
    • Glucocorticosteroids
    • Cold
    • Stress
    • Prior respiratory infections (including influenza)
    • Daycare attendance
    • Homeless shelters
    • Military training
    • Prisons
    • Malnutrition
    • Lack of exposure to breast milk
  • Defects in clearance of pneumococci from the blood
    • Congenital asplenia
    • Splenectomy
    • Autosplenectomy due to sickle cell disease
  • Defects in clearance from sinopulmonary tissue or inflammatory conditions
    • Asthma
    • COPD
    • Cigarette smoking
    • Influenza/respiratory viral infections
  • Defective antibody formation
    • Primary
      • Congenital agammaglobulinemia
      • Common variable hypogammaglobulinemia
      • Selective immunoglobulin G (IgG) subclass deficiency
    • Secondary
      • Lymphoma
      • Chronic lymphocytic leukemia
      • Multiple myeloma
      • HIV infection
  • Defective complement (primary or secondary): Absent or decreased amounts of C1, C2, C3 or C4
  • Abnormalities in polymorphonuclear leukocytes
    • Decreased levels associated with cyclic neutropenia, drug-induced neutropenia, or aplastic anemia
    • Decreased function caused by conditions such as alcoholism, cirrhosis, diabetes mellitus, renal insufficiency, and steroid therapy
  • Other
    • Age (children <2 y and elderly persons)
    • Fatigue
    • Chronic disease
    • Hospitalization3

More on Pneumococcal Infections

Overview: Pneumococcal Infections
Differential Diagnoses & Workup: Pneumococcal Infections
Treatment & Medication: Pneumococcal Infections
Follow-up: Pneumococcal Infections
Multimedia: Pneumococcal Infections
References
Further Reading

References

  1. Ghaffar F, Friedland IR, McCracken GH Jr. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J. Jul 1999;18(7):638-46. [Medline].

  2. Dagan R, Greenberg D, Jacobs MR. Pneumococcal Infections. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan SL. Textbook of Pediatric Infectious Diseases. 1. 5th. Philadelphia, Pennsylvania: Saunders (Elsevier Science); 2004:1204-1258/90.

  3. Musher DM. Streptococcus pneumoniae. In: Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 2. 6th. Philadelphia, Pennsylvania: Elsevier, Churchill Livingstone; 2005:197.

  4. WHO Initiative for Vaccine Research Division. Acute Respiratory Infections, Streptococcus pneumoniae. World Health Organization (WHO). Available at http://www.who.int/vaccine_research/diseases/ari/en/index5.html#vaccine.

  5. Eskola J, Black S, Shinefield H. Pneumococcal Conjugate Vaccines. In: Plotkin SA, Orenstein WA. Vaccines. 4th. Philadelphia, PA: Elsevier Inc; 2004:23.

  6. Scott JA. The preventable burden of pneumococcal disease in the developing world. Vaccine. Mar 22 2007;25(13):2398-405. [Medline].

  7. Fedson DS, Scott JA. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine. Jul 30 1999;17 Suppl 1:S11-8. [Medline].

  8. World Health Organization. Weekly Epidemiological Record. March/2007. [Full Text].

  9. WHO.INT; Immunization, Vaccines and Biologicals Division. Pnuemococcal Vaccines. WHO.INT. Available at http://www.who.int/vaccines/en/pneumococcus.shtml. Accessed April 2003.

  10. Brunton S, Carmichael BP, Colgan R, Feeney AS, Fendrick AM, Quintiliani R, et al. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. Am J Manag Care. Oct 2004;10(10):689-96. [Medline].

  11. Peter G, Klein JO. Streptococus pneumoniae. In: Long SS, Pickering LK, Prober CG. Principles and Practices of Pediatric Infectious Diseases. 2nd. Philadelphia, PA: Churchill Livingstone (Elsevier); 2002:739-746/131.

  12. Bradley JS, Kaplan SL, Tan TQ, Barson WJ, Arditi M, Schutze GE, et al. Pediatric pneumococcal bone and joint infections. The Pediatric Multicenter Pneumococcal Surveillance Study Group (PMPSSG). Pediatrics. Dec 1998;102(6):1376-82. [Medline].

  13. van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis. Mar 2004;4(3):139-43. [Medline].

  14. Committee on Infectious Diseases; American Academy of Pediatrics. Pneumococcal Infections. In: Pickering LK, Baker CJ, Long SS, McMillan JA. Red Book 2006 Report of the Committee on Infectious Diseases. 27th. American Academy of Pediatrics; 2006:525-37.

  15. Active Bacterial Core Surveillance (ABCs) Report; Emerging Infections Program Network; Streptococcus pneumoniae [database online]. CDC website: CDC; Jan 2005. Updated 2004.

  16. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis. Apr 15 2003;36(8):963-70. [Medline].

  17. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. Dec 28 2000;343(26):1917-24. [Medline].

  18. Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother. Jun 2004;48(6):2101-7. [Medline].

  19. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. Mar 1 2007;44 Suppl 2:S27-72. [Medline].

  20. ACIP. Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). cdc.gov: CDC; April 1997. 1-24. [Full Text].

  21. ACIP. Preventing Pneumococcal Disease Among Infants and Young Children; Recommendations of the Advisory Committee on Immunization Practices (ACIP). cdc.gov: CDC; October 2000. 1-38. [Full Text].

  22. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. Dec 2001;20(12):1105-7. [Medline].

  23. Kaplan SL, Mason EO Jr, Wald ER, Schutze GE, Bradley JS, Tan TQ, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. Mar 2004;113(3 Pt 1):443-9. [Medline].

  24. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. Apr 25 2007;297(16):1784-92. [Medline].

  25. Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med. Jul 11 2005;165(13):1533-40. [Medline].

  26. American Academy of Pediatrics/American Academy of Family Physicians. Clinical Practice Guideline: Diagnosis and Management of Acute Otitis Media. www.aafp.org. Available at http://www.aafp.org/online/etc/medialib/aafp_org/documents/clinical/clin_recs/otitismedia.Par.0001.File.dat/final_aom.pdf. Accessed March 2004.

  27. Donowitz GR, Mandell GL. Acute Pneumonia. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseses. (1). 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000:717-43.

  28. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. Apr 4 1997;46:1-24. [Medline].

Keywords

Streptococcus pneumoniae, S pneumoniae, pneumococcus , pneumococci, upper respiratory tract disease, lower respiratory tract disease, upper respiratory disease, lower respiratory disease, respiratory disease, community-acquired pneumonia, CAP, pneumonia, lung infection, respiratory infection, pneumococcal disease, otitis media, pharyngeal infection, nosocomial pneumonia, hospital-acquired pneumonia, bronchopneumonia, broncho-pneumonia, meningitis, tracheobronchitis, acute sinusitis, sinusitis, pneumococcal sepsis, pneumococcal pneumonia, pneumococcal conjunctivitis, pneumococcal otitis media, pneumococcal sinusitis, acute exacerbations of chronic bronchitis, AECB, pneumococcal meningitis, pneumococcal bacteremia, pneumococcal joint infection, pneumococcal bone infection, pneumococcal soft tissue infection, pneumococcal osteomyelitis, pneumococcal peritonitis, pneumococcal endocarditis, pneumococcal pericarditis, pneumococcal septic arthritis

Contributor Information and Disclosures

Author

Dawn F Muench, MD, Assistant Professor of Pediatrics, Uniformed Services University of the Health Sciences; Fellow in Pediatric Infectious Disease, Department of Pediatrics, National Capital Consortium, Walter Reed Army Medical Center
Dawn F Muench, MD is a member of the following medical societies: American Academy of Pediatrics, Armed Forces Infectious Diseases Society, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Coauthor(s)

Michael Rajnik, MD, Assistant Professor, Department of Pediatrics, Acting Program Director, Pediatric Infectious Disease Fellowship Program, Uniformed Services University of the Health Sciences
Michael Rajnik, MD is a member of the following medical societies: American Academy of Pediatrics, Armed Forces Infectious Diseases Society, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Medical Editor

Thomas Herchline, MD, Professor of Medicine, Wright State University Boonshoft School of Medicine; Medical Director, Public Health, Dayton and Montgomery County, Ohio
Thomas Herchline, MD is a member of the following medical societies: American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Aaron Glatt, MD, Professor of Clinical Medicine, New York Medical College; President and CEO, Former Chief Medical Officer, Departments of Medicine and Infectious Diseases, New Island Hospital
Aaron Glatt, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physician Executives, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Infectious Diseases Society of America, International AIDS Society, and Society for Healthcare Epidemiology of America
Disclosure: Nothing to disclose.

CME Editor

Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital
Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.